摘要
生物制药行业作为现代医药领域的核心驱动力,在维护国民健康、推动经济发展与科技进步等层面,发挥着无可替代的关键作用,相较于全球医药创新前沿阵营,我国医药产业在创新能级上仍存在明显代际差。本文全面分析了我国生物制药产业的发展现状,深入探讨了产业发展过程中面临的问题与挑战,系统研究了国际生物制药产业的发展趋势与竞争态势,进而从强化政策扶持力度、强化创新驱动、加强人才培养、完善产业链条、加强国际合作等方面提出了符合我国国情的生物制药产业发展战略和对策建议,推动我国从生物制药大国向生物制药强国转变,为人民群众提供更加优质、高效、便捷的医疗服务,助力健康中国建设。
The biopharmaceutical industry,serving as the core driving force in the realm of modern medicine,assumes an irreplaceable role in safeguarding national health,propelling economic development,and fostering technological advancements.When juxtaposed with the global vanguard of pharmaceutical innovation,China’s pharmaceutical industry still exhibits a notable generational disparity in terms of innovation capabilities.This study analyzes the current development status of China’s biopharmaceutical industry,delving into the issues and challenges encountered during its development.It also examines the development trends and competitive landscape of the international biopharmaceutical industry.Subsequently,considering China’s national circumstances,this study proposes development strategies and policy recommendations for the biopharmaceutical industry in several aspects.These include intensifying policy support,bolstering innovation-driven impetus,strengthening talent cultivation,optimizing the industrial chain,and enhancing international cooperation.The overarching aim is to facilitate China’s transition from a large biopharmaceutical nation to a strong biopharmaceutical power,thereby offering the public more high-quality,efficient,and accessible medical services and contributing to the construction of the Healthy China initiative.
作者
徐来
余河水
王兆品
李颖
杨晶晶
陈香美
顾晓松
Xu Lai;Yu Heshui;Wang Zhaopin;Li Ying;Yang Jingjing;Chen Xiangmei;Gu Xiaosong(Key Laboratory of Neuroregeneration,Nantong University/Co-innovation Center of Neuroregeneration,Nantong 226001,Jiangsu,China;College of Pharmaceutical Engineering of Traditional Chinese Medicine,Tianjin University of Traditional Chinese Medicine,Tianjin 301617,China;School of Medicine,Zhejiang University,Hangzhou 310058,China;National Institute for Food and Drug Control,Beijing 102629,China;School of Pharmaceutical Sciences,Hainan University,Haikou 570228,China;Department of Nephrology,First Medical Center of Chinese PLA General Hospital/State Key Laboratory of Kidney Diseases,Beijing 100017,China)
出处
《中国工程科学》
北大核心
2025年第6期92-105,共14页
Strategic Study of CAE
基金
中国工程院咨询项目“我国生物医药产业高质量发展战略研究”(2023-XBZD-11)。
关键词
生物制药
人工智能
药物递送
细胞治疗
biopharmaceuticals
artificial intelligence
drug delivery
cell therapy
